All In Biotech

Drug Trial Radar · NCT07524322

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Apr 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Regor Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Conditions

  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • PIK3CA Mutation
  • HER2- Negative Breast Cancer
  • Advanced Breast Cancer
  • Unresectable Solid Tumor
  • Hormone Receptor Positive Tumor
  • Cervical Cancer

Interventions

  • RGT-490Drug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs)Time frame: 4 weeks (1 cycle)
  2. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • START Los Angeles

    Los Angeles, California · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • NEXT San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.